Aldesleukin 22000000 UNT Injection [Proleukin]

Known as: ALDESLEUKIN 1.1 mg in 1 mL INTRAVENOUS INJECTION [PROLEUKIN], Proleukin 22,000,000 UNT Injection, aldesleukin 1.1 mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [Proleukin] 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Regulatory T cells (Tregs) play an important role in preventing effector T-cell (Teff) targeting of self-antigens that can lead… (More)
Is this relevant?
2014
2014
A multi-center study of high dose Aldesleukin (Proleukin®(HD IL-2) + Vemurafenib Zelboraf®) therapy in patients with BRAF… (More)
  • figure 1
Is this relevant?
2014
2014
Prometheus Laboratories, San Deigo, CA, USA Full list of author information is available at the end of the article Figure 1 Open… (More)
  • figure 1
Is this relevant?
2011
2011
BACKGROUND The objective of this study was to evaluate the recurrence-preventing effect of intravesical instillations of… (More)
Is this relevant?
2007
2007
BACKGROUND Local therapy with IL-2 may be very effective in the treatment of different forms of cancer. The aim of this study was… (More)
  • figure 1
  • table I
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2004
2004
Die AUO nimmt derzeit aktiv an der internationalen EORTC-Studie 30012, A Randomized Controlled Trial of Interferon-α, Interleukin… (More)
Is this relevant?
2001
2001
Interleukin-2 (IL-2) kommt aufgrund seiner immunstimulatorischen Wirkung auf T-Zellen in der Tumortherapie von Karzinomen, Leuk… (More)
Is this relevant?